These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 28626220)

  • 1. A phase 3 randomized placebo-controlled trial of darbepoetin alfa in patients with anemia and lower-risk myelodysplastic syndromes.
    Platzbecker U; Symeonidis A; Oliva EN; Goede JS; Delforge M; Mayer J; Slama B; Badre S; Gasal E; Mehta B; Franklin J
    Leukemia; 2017 Sep; 31(9):1944-1950. PubMed ID: 28626220
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase 2, single-arm trial to evaluate the effectiveness of darbepoetin alfa for correcting anaemia in patients with myelodysplastic syndromes.
    Gabrilove J; Paquette R; Lyons RM; Mushtaq C; Sekeres MA; Tomita D; Dreiling L
    Br J Haematol; 2008 Jul; 142(3):379-93. PubMed ID: 18540943
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Darbepoetin alfa for anemia in patients with low or intermediate-1 risk myelodysplastic syndromes and positive predictive factors of response.
    Villegas A; Arrizabalaga B; Fernández-Lago C; Castro M; Mayans JR; González-Porras JR; Duarte RF; Remacha AF; Luño E; Gasquet JA
    Curr Med Res Opin; 2011 May; 27(5):951-60. PubMed ID: 21381892
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized controlled trial comparing darbepoetin alfa doses in red blood cell transfusion-dependent patients with low- or intermediate-1 risk myelodysplastic syndromes.
    Jang JH; Harada H; Shibayama H; Shimazaki R; Kim HJ; Sawada K; Mitani K
    Int J Hematol; 2015 Oct; 102(4):401-12. PubMed ID: 26323997
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Erythropoiesis-stimulating agents in the treatment of anemia in myelodysplastic syndromes: a meta-analysis.
    Moyo V; Lefebvre P; Duh MS; Yektashenas B; Mundle S
    Ann Hematol; 2008 Jul; 87(7):527-36. PubMed ID: 18351340
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized, double-blind, placebo-controlled trial of every-3-week darbepoetin alfa 300 micrograms for treatment of chemotherapy-induced anemia.
    Hernandez E; Ganly P; Charu V; Dibenedetto J; Tomita D; Lillie T; Taylor K;
    Curr Med Res Opin; 2009 Sep; 25(9):2109-20. PubMed ID: 19601709
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of every-2-week darbepoetin alfa in patients with anemia of cancer: a controlled, randomized, open-label phase II trial.
    Charu V; Belani CP; Gill AN; Bhatt M; Tomita D; Rossi G; Ben-Jacob A
    Oncologist; 2007 Jun; 12(6):727-37. PubMed ID: 17602062
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): primary analysis of a phase 3, open-label, randomised, controlled trial.
    Della Porta MG; Garcia-Manero G; Santini V; Zeidan AM; Komrokji RS; Shortt J; Valcárcel D; Jonasova A; Dimicoli-Salazar S; Tiong IS; Lin CC; Li J; Zhang J; Pilot R; Kreitz S; Pozharskaya V; Keeperman KL; Rose S; Prebet T; Lai Y; Degulys A; Paolini S; Cluzeau T; Fenaux P; Platzbecker U
    Lancet Haematol; 2024 Sep; 11(9):e646-e658. PubMed ID: 39038479
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized double-blind trial of darbepoetin alfa in patients with symptomatic heart failure and anemia.
    Ghali JK; Anand IS; Abraham WT; Fonarow GC; Greenberg B; Krum H; Massie BM; Wasserman SM; Trotman ML; Sun Y; Knusel B; Armstrong P;
    Circulation; 2008 Jan; 117(4):526-35. PubMed ID: 18195176
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial.
    Platzbecker U; Della Porta MG; Santini V; Zeidan AM; Komrokji RS; Shortt J; Valcarcel D; Jonasova A; Dimicoli-Salazar S; Tiong IS; Lin CC; Li J; Zhang J; Giuseppi AC; Kreitz S; Pozharskaya V; Keeperman KL; Rose S; Shetty JK; Hayati S; Vodala S; Prebet T; Degulys A; Paolini S; Cluzeau T; Fenaux P; Garcia-Manero G
    Lancet; 2023 Jul; 402(10399):373-385. PubMed ID: 37311468
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Darbepoetin alfa administered every three weeks is effective for the treatment of chemotherapy-induced anemia.
    Boccia R; Malik IA; Raja V; Kahanic S; Liu R; Lillie T; Tomita D; Clowney B; Silberstein P
    Oncologist; 2006 Apr; 11(4):409-17. PubMed ID: 16614237
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-Term Efficacy of Erythropoiesis-Stimulating Agents in Patients with Low-Risk or Intermediate-1-Risk Myelodysplastic Syndrome: Multicenter Real-Life Data.
    Aslaner Ak M; Gedük A; Acar İH; Polat MG; Sunu C; Bolaman AZ; Hacıbekiroğlu T; Güvenç B; Ertop Ş
    Turk J Haematol; 2023 May; 40(2):92-100. PubMed ID: 36799095
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Randomized, Double-Blind, Placebo-Controlled, Phase III Noninferiority Study of the Long-Term Safety and Efficacy of Darbepoetin Alfa for Chemotherapy-Induced Anemia in Patients With Advanced NSCLC.
    Gascón P; Nagarkar R; Šmakal M; Syrigos KN; Barrios CH; Sánchez JC; Zhang L; Henry DH; Gordon D; Hirsh V; Kubota K; Orlov S; Thomas G; Steinmetz T; Kang JH; Tomita DK; Fleishman AN; Park JK; De Oliveira Brandao C
    J Thorac Oncol; 2020 Feb; 15(2):190-202. PubMed ID: 31629060
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treating anemia of cancer with every-4-week darbepoetin alfa: final efficacy and safety results from a phase II, randomized, double-blind, placebo-controlled study.
    Gordon D; Nichols G; Ben-Jacob A; Tomita D; Lillie T; Miller C
    Oncologist; 2008 Jun; 13(6):715-24. PubMed ID: 18586927
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High response rate and improved exercise capacity and quality of life with a new regimen of darbepoetin alfa with or without filgrastim in lower-risk myelodysplastic syndromes: a phase II study by the GFM.
    Kelaidi C; Beyne-Rauzy O; Braun T; Sapena R; Cougoul P; Adès L; Pillard F; Lamberto C; Charniot JC; Guerci A; Choufi B; Stamatoullas A; Slama B; De Renzis B; Ame S; Damaj G; Boyer F; Chaury MP; Legros L; Cheze S; Testu A; Gyan E; Béné MC; Rose C; Dreyfus F; Fenaux P
    Ann Hematol; 2013 May; 92(5):621-31. PubMed ID: 23358617
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Darbepoetin alfa 300 or 500 μg once every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia.
    Auerbach M; Silberstein PT; Webb RT; Averyanova S; Ciuleanu TE; Shao J; Bridges K
    Am J Hematol; 2010 Sep; 85(9):655-63. PubMed ID: 20661916
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized, open-label, multicenter trial of immediate versus delayed intervention with darbepoetin alfa for chemotherapy-induced anemia.
    Charu V; Saidman B; Ben-Jacob A; Justice GR; Maniam AS; Tomita D; Rossi G; Rearden T; Glaspy J
    Oncologist; 2007 Oct; 12(10):1253-63. PubMed ID: 17962619
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Darbepoetin alfa for the treatment of anemic patients with low- and intermediate-1-risk myelodysplastic syndromes.
    Stasi R; Abruzzese E; Lanzetta G; Terzoli E; Amadori S
    Ann Oncol; 2005 Dec; 16(12):1921-7. PubMed ID: 16166176
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized trial of darbepoetin alfa for treatment of renal anemia at a reduced dose frequency compared with rHuEPO in dialysis patients.
    Vanrenterghem Y; Bárány P; Mann JF; Kerr PG; Wilson J; Baker NF; Gray SJ;
    Kidney Int; 2002 Dec; 62(6):2167-75. PubMed ID: 12427142
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Darbepoetin alfa in anemia of myelodysplastic syndromes: present and beyond.
    Kelaidi C; Fenaux P
    Expert Opin Biol Ther; 2010 Apr; 10(4):605-14. PubMed ID: 20201708
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.